Repligen and Novasign Partner to Drive Bioprocessing Digitalization

Repligen Corporation has announced a strategic partnership with Novasign aimed at accelerating the digital transformation of bioprocessing. The collaboration will focus on integrating Novasign’s advanced machine learning and modeling workflows into Repligen’s tangential flow filtration (TFF) systems, further enhancing automation, real-time control, and process efficiency.

As part of the agreement, Repligen will also make a strategic investment in Novasign to support the company’s growth and operational scale-up.

The integration of Novasign’s AI-powered modeling technology is expected to bolster Repligen’s portfolio of process analytical technology (PAT)-enabled systems and pave the way for future AI-driven innovations. This includes the use of digital twins—virtual models of bioprocesses that allow for predictive control and faster development cycles.

“This partnership underscores Repligen’s dedication to advancing smart digital manufacturing,” said Ralf Kuriyel, Senior Vice President of R&D at Repligen. “By integrating our automated systems with Novasign’s digital modeling, we’re offering our customers powerful tools to accelerate development and scale-up with greater efficiency and reliability.”

Novasign, known for its expertise in bioprocessing, modeling, and software development, provides AI-driven tools applicable across cultivation, harvest, filtration, and chromatography. Its flexible modeling solutions help extract insights from data across various bioprocessing stages, enabling smarter development and monitoring while reducing time, cost, and risk.

Mark Duerkop, CEO of Novasign, highlighted the impact of the partnership: “The fusion of intelligent modeling, PAT, and smart devices will enable the industry to cut development costs and deepen process understanding. This collaboration is a major milestone for us, and we’re proud to advance our role in bioprocess digitalization alongside Repligen.”

The partnership builds on previous joint efforts between the two companies and represents a significant step toward smarter, more efficient biomanufacturing.